Betamethasone diproprionate/calcipotriol

Drug Profile

Betamethasone diproprionate/calcipotriol

Alternative Names: Calcipotriene/betamethasone propionate; Calcipotriol/betamethasone diproprionate; Daivobet; Daivobet 50/500 Ointment; Daivobet Gel; Dovobet; Enstilar; LEO 90100 aerosol foam; LEO 90105; LEO-80185; LEO-90100; LEO90100 cutaneous spray ointment - LEO Pharma; LP-0113; Taclonex; Taclonex Scalp; Xamiol

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Developer Kyowa Hakko Kirin; LEO Pharma
  • Class Anti-inflammatories; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriasis

Most Recent Events

  • 22 Jun 2017 LEO Pharma and Kyowa Hakko Kirin agree to co-promote Betamethasone diproprionate/calcipotriol topical gel formulation in Japan for Plaque psoriasis
  • 22 Jun 2017 Preregistration for Plaque psoriasis in Japan (Topical,gel)
  • 15 Feb 2017 LEO Pharma completes the PSO-LONG trial in Plaque psoriasis in United Kingdom (Topical, Aerosol) (NCT02899962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top